Compare AU
Compare CURE vs. GLIN
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the iShares Ftse Gbl Infrastructure (Aud Hedged) ETF (GLIN). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | GLIN | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 5 |
Median incremental investment | $624.65 | $1,000.00 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,353.14 | $5,822.11 |
Average age group | > 35 | > 35 |
Key Summary
CURE | GLIN | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | GLIN.AX was created on 2023-05-16 by iShares. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 928.27m in AUM and 135 holdings. The Fund aims to provide investors with the performance of an index, before fees and expenses (including the cost of hedging). The index is designed to measure the AUD hedged performance of global developed market infrastructure securities. |
Top 3 holdings | AbbVie Inc (2.62 %) Alnylam Pharmaceuticals Inc (2.59 %) Amgen Inc (2.59 %) | Aena SME SA (4.96 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (76.69 %) Energy (14.19 %) Industrials (12.71 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (60.50 %) Canada (10.53 %) Australia (6.00 %) |
Management fee | 0.45 % | 0.15 % |
Key Summary
CURE | GLIN | |
|---|---|---|
Issuer | Global X | iShares |
Tracking index | S&P Biotechnology Select Industry | FTSE Developed Core Infrastructure 50/50 Index - USD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.15 % |
Price | $46.83 | $26.94 |
Size | $33.491 million | $926.154 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 0.97 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 06/06/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | GLIN | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 5 |
Median incremental investment | $624.65 | $1,000.00 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,353.14 | $5,822.11 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | GLIN | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | GLIN |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |